Navigate to the Schizophrenia: Current and Potential Future Care threaded discussion link below and create a post identifying the question that you will be
addressing. Please take time to look at other initial posts to avoid duplication. This should be done before extensive research is conducted.
1. Cariprazine is a newer atypical antipsychotic that has partial agonism on the D3 receptor. What benefits might this have for the patient? Cariprazine also
has a long half-life and the author of the text indicates that it could be marketed as a weekly or even monthly oral option for schizophrenia. Can you find any
studies that would indicate its effectiveness as a long acting oral option?
2. It is known that patients with long term psychotic illnesses are at higher risk of cognitive decline. Is there any evidence to support the use of cognitionenhancing medications to slow cognitive decline in patients with schizophrenia or psychosis?
3. According to Stahl, there is some question whether prophylactic use of antipsychotics can prevent the development of schizophrenia. What studies have
examined this question? Provide an evaluation of the studies that have been conducted on the topic, identifying any potential design flaws or biases.